35879-53-9

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-(AMINOMETHYL)CYCLOHEXANECARBOXYLATE is used as a building block for the synthesis of medications, primarily due to its structural properties that can be incorporated into the molecular design of new drugs. Its presence in drug formulations is aimed at enhancing the therapeutic effects for the treatment of neurological disorders and as a local anesthetic, leveraging its chemical reactivity and functional groups.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 4-(AMINOMETHYL)CYCLOHEXANECARBOXYLATE is utilized for the development of new pesticides. Its unique chemical structure allows for the creation of novel compounds that can effectively target and control pests, thereby contributing to improved crop protection strategies and agricultural productivity.

InChI:InChI=1/C10H19NO2/c1-2-13-10(12)9-5-3-8(7-11)4-6-9/h8-9H,2-7,11H2,1H3

Upstream product

• 64-17-5 ethanol 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 98837-34-4 ethyl 3-hydroxy-2-methylenebutanoate 
• 107-13-1 acrylonitrile 
• 140-88-5 ethyl acrylate 

Downstream Products

• 180046-90-6 trans 4-(tert-butyloxycarbonylaminoethyl)cyclohexaneacetaldehyde 
• 438190-93-3 1'-(trans-4-Ethoxycarbonyl-cyclohexylmethyl)carbamoyl-spiro [isobenzofuran-1,4'piperidin]3-one 

Relevant academic research and scientific papers

Production of Copolyester Monomers from Plant-Based Acrylate and Acetaldehyde

PCTA is an important copolyester that has been widely used in our daily necessities. Currently, its monomers are industrially produced from petroleum-derived xylene. To reduce the reliance on fossil energy, we herein disclose an alternative route to acces

Gadolinium Complex of DO3A-Tranexamates Conjugate

The present invention relates to an MRI contrast agent including a gadolinium complex. More specifically, The present invention relates to DO3A-tranexamic acid having a structure of Chemical formula 1, or a ester compound thereof, and a gardolinium complex of the same DO3A-tranexamic acid and the ester compound. According to the present invention, DO3A-tranexamic acid and the ester compound thereof can be produced; and the gardolinium complex can be produced by using the same compound. Gradolinium compounds, produced by a method of the present invention, have thermodynamic kinetic stability and a relaxation rate similar with that of a clinical contrast agent which is commercially used at present. Therefore, according to the present invention, the gardolinium complex can be widely used as a contrast agent for MRI.COPYRIGHT KIPO 2015

A structure-activity analysis of biased agonism at the dopamine D2 receptor

Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs. A number of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia. As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor. We have generated SAR based on a novel D2R partial agonist, tert-butyl (trans-4-(2-(3,4-dihydroisoquinolin- 2(1H)-yl)ethyl)cyclohexyl)carbamate (4). This ligand shares structural similarity to cariprazine (2), a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points. We synthesized a number of derivatives of 4 with subtle structural modifications, including incorporation of cariprazine fragments. By combining pharmacological profiling with analytical methodology to identify and to quantify bias, we have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group containing the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.

Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them

A compound of formula (I) selected from: wherein: X represents oxygen or sulphur, Y represents oxygen, —NH— or —N(C1-C6)alkyl-, Ra represents hydrogen, halogen, (C1-C3)alkyl, hydroxyl or (C1-C3)alkoxy, Rb represents hydrogen, halogen or (C1-C3)alkyl, A represents phenyl, pyridyl, (C5-C6)cycloalkyl or (C5-C6)cycloalkenyl, R1 and R2 each represent a group selected from hydrogen, halogen, cyano, nitro, haloalkyl, haloalkoxy, alkyl, alkenyl, alkynyl, —OR4, —NR4R5, —S(O)nR4, —C(O)R4, —CO2R4, —O—C(O)R4, —C(O)NR4R5, —NR5—C(O)R4, —NR5—SO2R4, -T-CN, -T-OR4, -T-OCF3, -T- NR4R5, -T-S(O)nR4, -T-C(O)R4, -T-CO2R4, -T-O—C(O)R4, -T-C(O)NR4R5, -T-NR4—C(O)R5, -T-NR4—SO2R5, —R6 and -T-R6 in which n, T, R4, R5 and R6 are as defined in the description, R3 represents an —R7 or —U—R11 group in which R7 represents hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U represents a linear or branched alkylene chain and R11 is defined in the description, their optical isomers or their addition salts with a pharmaceutically acceptable acid or base, and their use as inhibitor of metalloproteinase and more specifically of metalloproteinase-12.